EyePoint Pharmaceuticals, Inc.

$EYPT gapped down today after its Phase 2 clinical trial for Duravyu didn’t meet the pre-specified primary endpoint.

Share this article:

About the Author:

EyePoint Pharmaceuticals, Inc.

Joey Ramson

PRISM Market View Alerts

Get your dose of PRISM Market
View news, right in your inbox

Mailchimp Signup